Akebia Therapeutics (AKBA) Income from Continuing Operations (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Income from Continuing Operations of 9054000.0 for Q1 2026, down 248.13% year-over-year from 6112000.0 in Q1 2025, and up 26.05% quarter-over-quarter from 12244000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Income from Continuing Operations for 14 consecutive years, with 9054000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 248.13% year-over-year to 9054000.0; the TTM figure through Mar 2026 stood at 20511000.0 (up 54.73% YoY), while the FY2025 annual figure was 5345000.0, up 92.3% from the prior year.
- Income from Continuing Operations improved to 9054000.0 in Q1 2026 per AKBA's latest filing, from 12244000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 31375000.0 in Q2 2022 and bottomed at 62281000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 13133352.94 across 5 years, with a median of 11172000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 138.24% — and 2024, when it tumbled 3814.01%.
- Akebia Therapeutics' Income from Continuing Operations stood at 4124000.0 in 2022, then soared by 114.89% to 614000.0 in 2023, then sank by 3814.01% to 22804000.0 in 2024, then jumped by 46.31% to 12244000.0 in 2025, then grew by 26.05% to 9054000.0 in 2026.
- Business Quant data shows AKBA's Income from Continuing Operations at 9054000.0 in Q1 2026, 12244000.0 in Q4 2025, and 540000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -8.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.91 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | 540,000.00 |
| Jun 30, 2025 | 247,000.00 |
| Mar 31, 2025 | 6.11 Mn |
| Dec 31, 2024 | -22.80 Mn |
| Sep 30, 2024 | -20.04 Mn |
| Jun 30, 2024 | -8.58 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | 614,000.00 |
| Sep 30, 2023 | -14.49 Mn |
| Jun 30, 2023 | -11.17 Mn |
| Mar 31, 2023 | -26.88 Mn |
| Dec 31, 2022 | -4.12 Mn |
| Sep 30, 2022 | -52.51 Mn |
| Jun 30, 2022 | 31.38 Mn |
| Mar 31, 2022 | -62.28 Mn |
| Dec 31, 2021 | -68.14 Mn |
| Sep 30, 2021 | -57.59 Mn |